Last $46.45 USD
Change Today -0.07 / -0.15%
Volume 1.4M
GSK On Other Exchanges
Symbol
Exchange
OTC US
New York
Xetra
London
Mexico
Frankfurt
As of 5:15 PM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc-spon adr (GSK) Key Developments

Clovis Oncology and GlaxoSmithKline Enter into Clinical Trial Collaboration

Clovis Oncology (CLVS) and GlaxoSmithKline (GSK) announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC). The Phase 1/2 trial of rociletinib given in combination with trametinib is planned to start in the first half of 2015. The trial is designed to assess the safety and activity of the combination in patients with EGFR mutant NSCLC who were previously treated with an EGFR tyrosine kinase inhibitor (TKI). This clinical trial is designed to test the hypothesis that the combination of two oral drugs targeting different cellular growth pathways, both often active in EGFR mutant NSCLC, will lead to augmented clinical benefit.

Several Companies Reportedly Eyes Mature Drugs of GlaxoSmithKline

Apollo Global Management, LLC (NYSE:APO) and other bidders intend to make an offer for all of the mature drugs of GlaxoSmithKline plc (LSE:GSK). The deal could be values at more than $3 billion, according to sources with direct knowledge of the situation. Apollo plans to acquire all of the products for sale while other suitors are only interested in purchasing regional businesses. The final offers will be accepted by GSK by early next week, the sources told Reuters. Other bidders include H. Lundbeck A/S (CPSE:LUN) and Kohlberg Kravis Roberts & Co. L.P. (NYSE:KKR) which has teamed up with manufacturer Norgine Pharmaceuticals Limited. Lupin Limited (NSE:LUPIN) was also interested in the auction, but at this point it is unclear if it is still taking part. GSK has appointed with Lazard Ltd to handle the auction and is hoping to find a buyer before the end of 2014. M&A Navigator added that spokesperson for GSK declined to comment. Representatives for Apollo, Norgine and Lundbeck did not comment when reached by Reuters, while KKR was unavailable for comment.

Apollo Global Reportedly Seeks To Acquire GSK's Mature Drugs

Apollo Global Management, LLC (NYSE:APO) is planning to bid for allGlaxoSmithKline plc (LSE:GSK) mature drugs, joining an auction expected to value the business at more than $3 billion, Reuters reproted citing four people familiar with the process. The private equity firm, run by Leon Black, could change the dynamic of the auction because it is ready to buy all the products on offer, while other potential buyers are looking to acquire only certain regional businesses. Apollo, GSK declined to comment.

GlaxoSmithKline plc Presents at UBS European Conference 2014, Nov-12-2014 10:00 AM

GlaxoSmithKline plc Presents at UBS European Conference 2014, Nov-12-2014 10:00 AM. Venue: London, United Kingdom. Speakers: Simon Dingemans, Chief Financial Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee.

GlaxoSmithKline Opens Non-Trading Branch in Cork

GlaxoSmithKline opened a non-trading branch in Cork into which it transferred $9.8 billion (EUR 7.9 billion) in assets as part of a Luxembourg tax structure. The Irish branch immediately loaned the assets back to its parent in Luxembourg in return for an interest-free loan. This meant that the $9.8 billion no longer featured when the Luxembourg company's wealth tax bill was being calculated by tax authorities in Luxembourg.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSK:US $46.45 USD -0.07

GSK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $160.09 USD +1.78
AbbVie Inc $69.20 USD +0.50
Bayer AG €120.46 EUR +0.40
Celgene Corp $113.69 USD +1.08
Novo Nordisk A/S kr272.90 DKK +3.20
View Industry Companies
 

Industry Analysis

GSK

Industry Average

Valuation GSK Industry Range
Price/Earnings 16.8x
Price/Sales 2.9x
Price/Book 13.7x
Price/Cash Flow 16.7x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.